Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
cancer
5
×
deals
5
×
detroit blog main
detroit top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
5
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
5
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
investing
national
cancer immunotherapy
clinical trials
fda
takeda pharmaceutical
vertex pharmaceuticals
aduro biotech
alzheimer's disease
biogen
What
roundup
bio
ahead
asco
companies
days
drug
admits
ago
alliance
alzheimer’s
ambien
american
annual
attendees
attention
big
biotech
biotechs
branded
bristol
buy
calls
camp’s
cancer
cash
changing
chicago
choices
city
classes
clinical
color
combinations
combinator
commissioner
community’s
consumers
costly
counterweight
Language
unset
Current search:
cancer
×
startups
×
deals
×
roche
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More